A detailed history of Nemes Rush Group LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Nemes Rush Group LLC holds 4,725 shares of VRTX stock, worth $2.29 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
4,725
Previous 4,716 0.19%
Holding current value
$2.29 Million
Previous $1.97 Billion 12.35%
% of portfolio
0.3%
Previous 0.28%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$392.81 - $485.53 $3,535 - $4,369
9 Added 0.19%
4,725 $2.21 Billion
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $7,338 - $8,029
-18 Reduced 0.38%
4,716 $1.97 Billion
Q4 2023

Feb 09, 2024

SELL
$343.0 - $410.68 $10,976 - $13,141
-32 Reduced 0.67%
4,734 $1.93 Billion
Q3 2023

Nov 09, 2023

SELL
$338.18 - $362.46 $6,087 - $6,524
-18 Reduced 0.38%
4,766 $1.66 Billion
Q2 2023

Aug 02, 2023

BUY
$314.42 - $351.91 $1.5 Million - $1.68 Million
4,784 New
4,784 $1.68 Billion

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $125B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Nemes Rush Group LLC Portfolio

Follow Nemes Rush Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nemes Rush Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nemes Rush Group LLC with notifications on news.